Seizures can be predicted more than 30 minutes before onset in patients with temporal lobe epilepsy
01 Mar 2023
Clinical Result
Seizures can be predicted more than 30 minutes before onset in patients with temporal lobe epilepsy, opening the door to a therapy using electrodes that could be activated to prevent seizures from happening, according to new research.
Seizures can be predicted more than 30 minutes before onset in patients with temporal lobe epilepsy, opening the door to a therapy using electrodes that could be activated to prevent seizures from happening, according to new research from UTHealth Houston.
The study, led by Sandipan Pati, MD, associate professor in the Department of Neurology with McGovern Medical School at UTHealth Houston, was recently published in NEJM Evidence, a publication of the New England Journal of Medicine.
"The ability to predict seizures before they occur is a major step forward in the field of epilepsy research," said Pati, senior author of the study and a member of the Texas Institute for Restorative Neurotechnologies at UTHealth Houston Neurosciences. "These findings are significant because they suggest that we may be able to develop more effective therapies for epilepsy, which could greatly improve the quality of life for patients who suffer from this condition."
Surgery is a common treatment for many patients with epilepsy. But when seizures affect larger areas of the brain, removing part of the brain surgically is not an option. Neuromodulation therapy could offer an alternative solution for patients with these seizures, Pati said.
Past studies of continuous electroencephalography (EEG) -- the measurement and recording of electrical activity in different parts of the brain -- have suggested that seizures in people with focal-onset epilepsies tend to occur during periods of heightened risk, represented by pathologic brain activities known as "pro-ictal states." The EEG-based detection of pro-ictal states is critical to the success of adaptive neuromodulation, with the early detection of seizures allowing electrodes to be applied therapeutically to the brain's seizure onset zone and thalamus.
To distinguish these pro-ictal states, Pati's team studied a prospective, consecutive series of 15 patients with temporal lobe epilepsy who underwent limbic thalamic recordings in addition to routine intracranial EEG for seizure localization. In total, they analyzed 1,800 patient hours of continuous EEG.
The researchers were able to detect pro-ictal states in patients with temporal lobe epilepsy at least 35 minutes before seizure onset. Pro-ictal states were distinguished at least 45 minutes before seizure onset in 13 of 15 participants. In two of 15 participants, they were distinguished up to 35 minutes prior.
While Pati believes that modulation of these brain regions during pro-ictal periods may be an effective therapeutic approach to the treatment of temporal lobe epilepsy, his theory still needs to be tested in clinical trials. However, this information could lead to the development of electrical or drug therapies aimed at preventing seizures.
"This study was made possible by the collaboration of a team of experts in neurology, neurosurgery, and neuroscience," he said. "It highlights the importance of interdisciplinary research in advancing our understanding of brain disorders."
Temporal lobe epilepsy is the most common seizure disorder, affecting some 50 million people globally. There are two temporal lobes, one on each side of the head behind the temples. Mesial temporal lobe epilepsy, which accounts for about 80% of all temporal lobe seizures, involves seizures starting in or near a part of the brain called the hippocampus, which controls memory and learning. Neocortical or lateral temporal lobe epilepsy involves seizures starting in the outer section of the temporal lobe.
Omar A. Alamoudi, PhD, postdoctoral research fellow in the Department of Neurology with McGovern Medical School at UTHealth Houston, contributed to the study. Other co-authors included Adeel Ilyas, MD, and Kristen O. Riley, MD, both with the University of Alabama at Birmingham.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.